Stem Cells and Multiple Sclerosis: What Is Established, What Is Investigational

Why this article is written the way it is

Multiple sclerosis is one of the conditions most heavily targeted by unscrupulous stem cell marketing worldwide. The reasons are painfully understandable. MS is unpredictable, it affects people in the prime of life, existing treatments manage rather than cure it, and progressive forms in particular have limited options. That combination — a serious disease, an uncertain future, and treatments that fall short of what patients want — creates exactly the vulnerability that bad actors exploit.

So this article is deliberately more cautious than an article about knee arthritis. If you are reading this because you or someone close to you has MS, you deserve to be told plainly what the evidence supports and where it stops, even when that is not what anyone wants to hear. We would rather you finish this page trusting us less and understanding more than the reverse.

The most valuable thing here is a distinction that most marketing deliberately blurs. When people say "stem cell therapy for MS," they may be referring to two treatments that share almost nothing: autologous hematopoietic stem cell transplantation (aHSCT) and mesenchymal stem cell (MSC) therapy. Different cells, different mechanisms, different settings, different risks, and vastly different evidence. Confusing them leads people to make decisions based on data that does not apply to what they are actually being offered. Our article on stem cell safety and scams is a useful companion to this one.

aHSCT: the intensive, hospital-based procedure

Autologous hematopoietic stem cell transplantation is essentially an immune system reset. The concept: MS involves the immune system attacking the myelin sheath around nerve fibers, so aHSCT aims to remove that misdirected immune system and rebuild it. Hematopoietic stem cells — blood-forming cells, not mesenchymal cells — are collected from the patient, the existing immune system is ablated with chemotherapy, and the stored cells are reinfused to reconstitute it.

This is a serious hospital procedure with a significant evidence base. Studies in carefully selected patients with highly active relapsing-remitting MS — people with continued relapses and new lesions despite disease-modifying therapy — have reported substantial reductions in relapse rate and new MRI activity, with a proportion of patients achieving prolonged periods without evident disease activity. In that specific population, aHSCT is a legitimate and increasingly studied option.

The qualifications matter enormously. This is not an outpatient infusion: it involves chemotherapy, a period of immune suppression with serious infection risk, weeks of recovery, and a real if small mortality risk in experienced centers. Patient selection is strict — it works best in younger patients with active inflammatory disease and shorter duration, and it is generally much less effective for progressive MS with established disability, because the damage is already done and immune reset does not rebuild lost myelin or axons. It requires a specialized transplant center and neurological co-management. If a clinic advertises "stem cell therapy for MS" as a simple infusion with a short stay, they are not offering aHSCT, whatever the evidence they cite.

MSC therapy: what regenerative clinics actually offer

Mesenchymal stem cell therapy is what the great majority of regenerative clinics, including ours, are actually referring to. MSCs are not blood-forming cells and they do not replace an immune system. They are best understood as signaling cells that release anti-inflammatory and immunomodulatory factors. The theoretical rationale in MS is that this immunomodulation might dampen the inflammatory process, and some laboratory work has suggested possible support for repair processes.

Here is the honest status: MSC therapy for multiple sclerosis is investigational. Clinical trials have been conducted and are ongoing, generally showing that infusion is reasonably well tolerated. What they have not demonstrated is consistent, reproducible, clinically meaningful benefit on the measures that matter most to patients — disability progression, relapse rate, and MRI activity — at the level that would justify calling it an established treatment. Results have been mixed and study designs variable.

What this means practically is that a patient considering MSC therapy for MS is considering an unproven intervention. That is not automatically an unreasonable thing to do — people make informed decisions about investigational options all the time — but it must be an informed decision, made with a neurologist's knowledge, with realistic expectations, and without abandoning treatments that do have evidence. What it is not is a cure, a reversal of established disability, or a replacement for disease-modifying therapy. Any clinic saying otherwise is misrepresenting the science, and that misrepresentation is common enough that it should be your default assumption until proven otherwise.

What no stem cell treatment can currently do

It helps to be explicit about the limits, because vague optimism is how patients get hurt. No stem cell treatment currently reverses established neurological disability in MS. If demyelination and axonal loss have already produced permanent deficits, no available cell therapy rebuilds those pathways. Marketing that shows dramatic before-and-after mobility improvements is either showing fluctuation that occurs naturally in MS, the effect of concurrent rehabilitation, or something less honest.

Similarly, no stem cell treatment cures MS. aHSCT can produce prolonged remission of inflammatory activity in selected patients, which is a genuinely significant outcome, but it is not the same as a cure and it does not restore lost function. And there is currently no cell therapy with established efficacy for primary or secondary progressive MS, which is precisely the group with the fewest options and therefore the group most aggressively marketed to.

One more caution deserves its own sentence, because it is where real harm happens: do not stop your disease-modifying therapy to pursue a stem cell treatment. Disease-modifying therapies have substantial evidence for reducing relapses and slowing progression. Discontinuing them, particularly certain agents where rebound disease activity is a recognized risk, can cause serious deterioration. Any clinic that encourages you to stop your neurologist's prescribed treatment has disqualified itself.

How to evaluate a clinic offering this

Given the marketing environment, vetting matters more here than almost anywhere in medicine. Ask directly: which type of stem cell therapy are you actually offering? If the answer is not immediately clear about whether it is aHSCT or MSC, that ambiguity is itself informative. Ask whether they will describe the treatment as investigational in writing. Ask what specific outcome they expect for your subtype and disability level, and whether they claim any effect on established disability.

Warning signs are fairly consistent: guaranteed improvement, testimonials in place of trial data, claims of curing or reversing MS, pressure to decide quickly, packages sold before any medical assessment, citing aHSCT trial results while offering MSC infusions, and any suggestion to discontinue disease-modifying therapy. A clinic that will not communicate with your neurologist is telling you something important about how it operates.

Good signs are the opposite and are unglamorous: a named licensed physician, willingness to say a treatment is unproven, insistence on reviewing your neurological records, explicit encouragement to keep your neurologist involved, and a candid discussion of the possibility of no benefit. At HealthBridge, regenerative therapies are administered by licensed physicians under Colombian regulations after individualized assessment, and our medical director Dra. Olga González leads that program. For MS specifically, we describe MSC therapy as investigational because that is what it is, and we will decline patients for whom we do not think it is appropriate.

A reasonable way to think about your decision

If you have MS and are considering this, a few principles will serve you better than more searching. First, establish which treatment you are actually being offered, and make sure the evidence being quoted applies to that treatment rather than the other one. Second, involve your neurologist — not as a formality, but because they know your subtype, your history and your MRI trajectory, and no clinic seeing you for the first time does.

Third, be honest with yourself about what you are hoping for. If you are hoping to halt highly active inflammatory relapsing disease and you are a younger patient failing disease-modifying therapy, aHSCT at a specialized center is a legitimate conversation to have with your neurologist. If you are hoping to recover function lost years ago to progressive disease, no current cell therapy offers that, and any clinic implying otherwise is trading on hope.

Fourth, do not let cost drive the decision. Treatment abroad is cheaper, and that matters, but the cheapest unproven treatment for a condition it cannot help is not a saving. For readers exploring the broader field, our pillar guide to stem cell therapy in Colombia covers the science, our autoimmune conditions article discusses related immunological reasoning, and our regenerative medicine program explains where we believe these therapies genuinely do and do not have a role. MS deserves a careful decision, and a careful decision starts with accurate information rather than encouraging language.